聖諾醫藥-B(02257.HK)2021年研發開支升173.1%至4070萬美元 繼續推進研發力度
格隆匯3月31日丨聖諾醫藥-B(02257.HK)公佈,截至2021年12月31日止年度,集團並無產生任何產品銷售收入;年內虧損為2.16億美元,同比擴大365.1%;公司擁有人應占年內虧損為2.13億美元,同比擴大386.8%;每股基本虧損為14.30美元。集團的絕大部分淨虧損來自按公平值計入損益的金融負債的公平值變動、研發開支、行政開支及上市開支。
截至2021年12月31日止年度,集團的其他收入由截至2020年12月31日止年度的80萬美元減少40萬美元或54.6%至40萬美元。該減少的主要原因是由於新冠病毒疫情,集團於2020年11月獲豁免償還政府貸款50萬美元。
截至2021年12月31日止年度,集團的研發開支由截至2020年12月31日止年度的1490萬美元增加2580萬美元或173.1%至4070萬美元。該增加主要歸因於:(i)董事薪酬及集團研發員工相關的員工成本;及(ii)臨牀試驗開支及臨牀前試驗開支。有關增加與集團持續投入研發以支持集團穩步推進及擴大候選藥物管線相符。
Sirnaomics正推進深入而廣泛的候選產品組合,包括集團正在美國就兩種主要產品臨牀候選藥物STP705及STP707進行7項的臨牀試驗,以及目前正在進行臨牀前研究的至少16種其他產品,其中七種產品預計將於不久的將來進入臨牀階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.